Internalization Of Antibody Fragments Directed Against FGFR1 | 63559
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1536

Journal of Biotechnology & Biomaterials received 1536 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Internalization of antibody fragments directed against FGFR1

Joint Event on 15th World Congress on Biotechnology And Biotech Industries Meet and 2nd International Conference on Enzymology and Molecular Biology

Lukasz Opalinski, Aleksandra Sokolowska-Wedzina, Martyna Szczepara, Malgorzata Zakrzewska and Jacek Otlewski

University of Wroclaw, Poland

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.070

Fibroblast growth factors (FGFs) and their plasma membrane-localized receptors (FGFRs) regulate signaling pathways that govern developmental processes and metabolism. Numerous tumors are characterized by the overproduction of FGFR and this is considered a bad prognostic factor for patient survival. Antibody drug conjugates (ADCs) targeting cancer cells with the elevated level of FGFR represent one of the most attractive therapeutic strategies. ADCs are composed of the antibodies raised against tumor-specific biomarkers linked to the highly cytotoxic drugs. After selective binding to the cancer cells ADCs are internalized and delivered to the lysosomes by intracellular vesicular transport system. The lysosomal proteolysis of ADCs results in the release of the cytotoxic drugs, leading to the cell death. A prerequisite for an ADC approach is efficient internalization of the antibody-target complex. Although the biology of FGFRs and their ligands has been broadly studied, the requirements for the effective internalization of antibodies that target FGFR remain elusive. We analyzed the internalization of antibody fragments in various formats that target FGFR1. The antibody fragments in the monovalent scFv format bind to FGFR1, but are not internalized into the model cells that overproduce FGFR1. In contrast, the same scFv proteins in the bivalent scFv-Fc format are efficiently internalized via FGFR1-mediated clathrin and dynamin dependent endocytosis. Interestingly, the receptor kinase function of FGFR1 is dispensable for endocytosis of scFv-Fc-FGFR1 complexes. Binding of the bivalent scFv-Fc induces FGFR1 dimerization without simultaneous receptor activation, suggesting that oligomerization of FGFR1 triggers receptor endocytosis.

Lukasz Opalinski has completed his MS in Biotechnology from the University of Wroclaw, Poland. In 2012, he obtained his PhD from the University of Groningen, Netherlands. His PhD work was focused on peroxisome proliferation and involvement of peroxisomes in antibiotics production by filamentous fungi. In 2012, he obtained EMBO Long Term Fellowship to study molecular mechanisms of mitochondria biogenesis at the University of Freiburg, Germany. Since 2015, he is working as a Faculty of Biotechnology in the University of Wroclaw, Poland, where he is working on the endocytosis of antibody fragments generated against FGFR1.

Email: [email protected]